CHD2 p.His1684Tyr
c.5050C>T · rs746849506 · VCV385132
Computational evidence
| Protein change | ||
| AlphaMissense | 0.0789 | likely benign |
|---|---|---|
| REVEL | 0.244 | benign-leaning |
| SaProt | LLR -6.42 | tolerated |
| ⇒ AlphaMissense, REVEL and SaProt all call this tolerated. | ||
| Splicing | ||
| SpliceAI | — | not assessed · no allele here is in the release |
| Constraint at this position | ||
| Conservation | phyloP 7.6 | GERP 1.4, phastCons 1 |
| Regional constraint | o/e 1.02 | unconstrained · MANE · 9,988 bp · p 0.77 · regional, not allelic |
| Overall | ||
| CADD | 19.6 | PHRED · no single calibrated threshold — expert panels disagree |
AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.
Population frequency
| Ancestry group | Frequency | 1 in |
|---|---|---|
| Middle Easterngrpmax | 0.0822% | 1,217 |
| European (non-Finnish) | 0.0175% | 5,728 |
| Admixed American | 0.0167% | 5,999 |
| Remaining individualsnot grpmax-eligible | 0.0112% | 8,925 |
| East Asian | 0.00446% | 22,446 |
| South Asian | 0.00439% | 22,767 |
| African / African-American | 0.00401% | 24,961 |
| Finnishnot grpmax-eligible | 0.00156% | 64,000 |
Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.
Variant & gene context
- Gene
- CHD2
- Protein
- p.His1684Tyr
- Coding
- c.5050C>T
- MANE Select
- NM_001271
- dbSNP
- rs746849506
- Type
- single nucleotide variant
- Location
- chr15:93020155 (GRCh38)
- Gene constraint
- LOEUF 0.174 · pLI 1.00 · ClinGen HI 3/3 (gnomAD)
- Structure
- AlphaFold pLDDT 60.81
- Residue 1684
- the 'disordered' region; a UniProt-annotated variant site (in dee94); a UniProt-annotated variant site (found in a patient with progressive myoclonus epilepsy; uncertain significance)
Disease context
developmental and epileptic encephalopathy 94 — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatmentsFor Lennox-Gastaut syndrome (Orphanet):
- Inheritance
- Autosomal dominant, Multigenic/multifactorial, Not applicable
- Onset
- Childhood, Infancy
- Prevalence
- 1-9 / 1 000 000 (Europe)
Similar variants
- CHD2 p.His1684Pro Likely pathogenic ★ ⚠ same residue
- CHD2 p.His1684Arg Conflicting classifications of pathogenicity ★ ⚠ same residue
- CHD2 p.His1684Asp Uncertain significance ★ ⚠ same residue
- CHD2 p.His1684Leu Uncertain significance ★ ⚠ same residue
- CHD2 c.1153+1G>C Pathogenic ★★ same condition
- CHD2 c.1809+1G>A Pathogenic/Likely pathogenic ★★ same condition
- CHD2 c.294+1G>T Likely pathogenic ★★ same condition
- CHD2 c.443+1G>A Pathogenic/Likely pathogenic ★★ same condition
Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →
Cite Sugi Variant
Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/chd2-p-his1684tyr (accessed [today's date]).
Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown